CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zosano Pharma Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zosano Pharma Corp
34790 Ardentech Ct
Phone: (510) 745-1200p:510 745-1200 FREMONT, CA  94555-3657  United States Fax: (302) 655-5049f:302 655-5049
The Company's Plan of Liquidation went into effect on 12/7/2022.
This company is no longer actively traded on any major stock exchange.
Business Summary
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. It is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202212/31/2021YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director StevenLo 55 10/21/2019 10/21/2019
Chief Financial Officer Christine E.Matthews 53 5/1/2020 2/1/2020
Lead Independent Director Kenneth R.Greathouse 69 6/10/2021 10/4/2017
3 additional Officers and Directors records available in full report.

Business Names
Business Name
The Macroflux Corporation
ZP Holdings, Inc.
ZP Opco, Inc
ZP Opco, Inc.
ZSAN
ZSANQ

General Information
Outstanding Shares: 4,898,737 (As of 4/12/2022)
Shareholders: 13
Stock Exchange: OTC
Federal Tax Id: 454488360
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 2, 2024